HOME >> MEDICINE >> NEWS
NOVANTRONE application for multiple sclerosis granted priority review by FDA

FDA review of NOVANTRONE data to be completed within six months

SEATTLE-Immunex Corporation (NASDAQ:IMNX) announced today that the U.S. Food and Drug Administration (FDA) has assigned priority review status to the new drug application (NDA) for NOVANTRONER (mitoxantrone for injection concentrate), indicating that the FDA will act on the application within six months of its date of submission. Immunex filed for expanded labeling for NOVANTRONE for the treatment of patients with secondary progressive multiple sclerosis (MS) on June 7, 1999.

"This is an important milestone in the development of NOVANTRONE as a potential treatment for people with secondary progressive MS," said Peggy V. Phillips, senior vice president, pharmaceutical development for Immunex. "We will continue to work closely with the FDA over the next six months as they evaluate these data."

The results of the pivotal NOVANTRONE Phase III study showed that NOVANTRONE had a statistically significant impact on reduction of relapse rate and delay in disability progression in patients with secondary progressive MS. Additional follow-up data presented at a recent international conference showed that one year after treatment was stopped, patients treated with NOVANTRONE continued to experience a reduction in their number of attacks, and a delay in their disability progression.

In the study, treatment with NOVANTRONE resulted in generally manageable side effects that were primarily mild to moderate. During the two-year trial, the most frequent side effects reported by patients treated in the 12 mg/m2 arm were nausea, alopecia (hair loss), upper respiratory tract infection, urinary tract infection, menstrual disorder, and transient neutropenia (a reduced number of white blood cells).

Multiple sclerosis is a chronic, debilitating disease of the central nervous system that, in its various stages, afflicts as many as 350,000 people in the Unit
'"/>

Contact: Lisa Crisera
criseral@immunex.com
206-389-4346
Immunex Corporation
19-Jul-1999


Page: 1 2

Related medicine news :

1. Immunex Files Supplemental NDA for NOVANTRONE
2. Considerable reductions in radiation exposure possible with 16-MDCT scanner on body applications
3. AstraZeneca submits regulatory application in Europe for use of Atacand(R) in heart failure
4. Roche files marketing application for Avastin with European health authorities
5. ENBREL application for early, active rheumatoid arthritis filed with the U.S. Food and Drug Administration
6. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
7. Research suggests possible blood test for multiple sclerosis
8. Mayo Clinic researchers announce promising next generation treatments for multiple myeloma
9. Good fats decrease multiple heart disease risk factors
10. Swallowing multiple magnets poses danger to children
11. Sleep disorders often indicate multiple health conditions

Post Your Comments:
(Date:3/26/2015)... Frencisco, CA (PRWEB) March 26, 2015 ... Center are proud to announce expanded offerings for Bay ... San Francisco Dental Implant Center has long been a ... have expanded its offerings to meet the strong demand ... in our reputation as a top-rated dental implant facility ...
(Date:3/26/2015)... Springs, FL (PRWEB) March 26, 2015 ... of the nation’s leading innovative specialty pharmacies, announces ... created position of Vice President of Pharmaceutical Relations. ... fostering beneficial connections with our pharmaceuticals partners and ... relationships in support of BioPlus’ expansion. , ...
(Date:3/26/2015)... In the key developed markets, the hypertension market value ... to decrease through 2020 at a negative CAGR (0.9%) to ... to 2017 at a 2.6% CAGR and a decline thereafter. ... surging penetration of fixed-dose combination drugs like Azor, Amturnide, Exforge ... and Tekamlo), a hike in the prevalence population to 190 ...
(Date:3/26/2015)... 2015 Leading nutritional supplement provider ... website: http://www.metabolicnutrition.com . The ultramodern, clean ... a user-friendly experience for consumers seeking information about ... new, enhanced Metabolic Nutrition website includes: , ... diverse line of products, conveniently broken down by ...
(Date:3/26/2015)... 26, 2015 Zane Benefits, the leader ... a new eBook, “The Comprehensive Guide To Interviewing For ... is the most important aspect of the hiring process. ... hiring the right way, possibly resulting in thousands of ... arduous undertaking, yet it’s essential to the success of ...
Breaking Medicine News(10 mins):Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 3Health News:BioPlus Specialty Pharmacy Expands Executive Team with New Position, Naming Sharon Ferrer as Vice President of Pharmaceutical Relations 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 3Health News:Metabolic Nutrition Launches Sleek New Website with New Features and Enhanced Consumer Information 2Health News:Zane Benefits Announces: New eBook: The Comprehensive Guide To Interviewing For Your Small Business 2
(Date:3/26/2015)... 2015 "Whether it,s our family, our friends, ... In a single sentence, Dr. Anthony Coyle ... Pfizer,s Centers for Therapeutic Innovation (CTI), sums ... at America,s biopharmaceutical companies. CTI,s unique ... patient foundations and the National Institutes of Health (NIH) ...
(Date:3/26/2015)... Mich. , March 26, 2015 Cardiologists ... have performed the Midwest,s first commercial implant of a ... for patients with non-valvular atrial fibrillation. The Watchman Left ... use of blood-thinning warfarin medication to reduce the risk ... common heart rhythm disorder affecting more than 5 million ...
(Date:3/26/2015)... 26, 2015 When they began experiencing ... PACS vendor their system would no longer be ... needed a better structured solution to support their ... due to its interface capabilities and its 2014 ... through to the hospital,s radiology department. Avreo,s experienced ...
Breaking Medicine Technology:Collaboration for Cures: Teaming Up to Advance Science and Save Lives 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 3Clinch Memorial Hospital Modernizes Workflow with Avreo interWORKS 2
Cached News: